BioLineRx Q2 Loss Widens to $4.3M; Going Concern Flagged as Cash Dwindles to $13.1M
BLRX sits 27% above its 52-week low of $2.15 on elevated volume (3.0× avg).
Summary
BioLineRx posted a wider Q2 loss and flagged going concern uncertainty with only $13.1 million in cash, while advancing its GLIX1 glioblastoma trial.
Key Events · Earnings and Guidance · BLRX
-
Q2 Net Loss Widens to $4.3M
Net loss for Q2 2026 was $4.3 million versus $3.9 million in Q2 2025, driven by higher R&D spending on GLIX1 and a $0.7 million increase in G&A expenses.
-
Going Concern Uncertainty Flagged
Management states a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern, with cash runway only into the first half of 2027.
-
Cash Position Drops to $13.1M
Cash, cash equivalents, and short-term bank deposits totaled $13.1 million as of June 30, 2026, down from $23.7 million at December 31, 2025.
-
GLIX1 Trial Advancing
Second of five planned cohorts is dosing in the Phase 1/2a glioblastoma trial; third cohort expected to commence dosing in September 2026.
Analysis · BLRX · Life Sciences
A widening Q2 2026 net loss of $4.3 million, up from $3.9 million a year earlier, underscores the financial strain at BioLineRx, where cash and short-term deposits have fallen to $13.1 million from $23.7 million at year-end. Management reiterated a going concern warning, citing material uncertainty about the company's ability to continue as a going concern, with runway only into the first half of 2027. The company is advancing GLIX1 in glioblastoma with the second cohort dosing and a third cohort expected in September, but the financial position is precarious — the $3.75 million offering announced August 28 provides only a short-term bridge. Adding to the overhang, the warrant amendment repricing 277,273 outstanding warrants to $2.78 with extended expiration further dilutes shareholders.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1872 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLRX was trading at $2.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.1M. The 52-week trading range was $2.15 to $4.56. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.